Step 1 of 2
Review key slides on the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in metastatic triple-negative breast cancer (mTNBC), with a focus on evidence guiding treatment selection and sequencing, emerging strategies for sequential ADC use, and practical approaches for preventing and managing treatment-related adverse events such as neutropenia, diarrhea, oral mucositis/stomatitis, ocular toxicities, and ILD/pneumonitis. The activity also highlights how biomarker status, prior therapy, toxicity profiles, and access-related factors influence individualized treatment decisions in clinical practice.